Antiparietal Cell Antibody Testing in B12 Deficiency
Antiparietal cell antibody (APCA) testing should be performed in patients with unexplained vitamin B12 deficiency, but the method matters critically—indirect immunofluorescence (IIF) is far superior to immunodot assays for diagnosing pernicious anemia, with 92% specificity compared to immunodot's poor performance. 1
Testing Strategy for Suspected Pernicious Anemia
When to Test for APCA
The 2024 NICE guidelines identify autoimmune conditions as key risk factors for B12 deficiency, including atrophic gastritis, coeliac disease, thyroid disease, Sjögren syndrome, and type 1 diabetes. 2 Testing for autoantibodies is appropriate when B12 deficiency is confirmed and pernicious anemia is suspected based on these risk factors or clinical presentation. 2
Which APCA Test to Order
Order APCA by indirect immunofluorescence (IIF), not immunodot assay. 1 The most recent high-quality evidence (2026) demonstrates that:
- APCA-IIF has 92% specificity for pernicious anemia 1
- APCA immunodot has poor specificity—it was positive in 96% of false positive cases (23/24 patients without PA) 1
- APCA-IIF titers ≥1:80 increase specificity to 96% 1
- IIF positivity was independently associated with PA diagnosis (OR 37.1,95% CI: 6.1-439.4) 1
Interpretation of Results
APCA-IIF positive (especially ≥1:80 titer): Strongly suggests pernicious anemia; proceed with intrinsic factor antibody (IFA) testing and consider endoscopy with gastric biopsy for definitive diagnosis. 1
APCA-IIF negative: Pernicious anemia is less likely, but IFA testing may still be warranted as IFA has higher specificity (98.6%) despite lower sensitivity (40.9%). 3
The Role of Intrinsic Factor Antibodies
IFA testing should be performed for confirmation, as it has the highest specificity (98.6%) for pernicious anemia. 3 However, IFA is only positive in approximately 40-70% of PA cases, making it insufficiently sensitive as a standalone test. 3, 4
The testing sequence matters: APCA-IIF serves as an effective screening test, with IFA reserved for confirmation. 4 Testing for IFA alone in APCA-negative patients has extremely low yield—only 0.47% of patients are IFA-positive when APCA is negative. 4
Frequency of Antibody Positivity
In patients with severe B12 deficiency (<73.8 pmol/L), 57% test positive for APCA and 14% for IFA, with over 60% showing positivity for either antibody. 5 This high detection rate supports routine antibody testing in severe B12 deficiency to identify otherwise undetected autoimmune atrophic gastritis. 5
Critical Caveat About APCA Specificity
Only 12.9% of APCA-positive patients actually have pernicious anemia by WHO criteria (anemia with Hb <13 g/dL for men or <12 g/dL for women, MCV ≥100 fL, and B12 <200 pg/mL). 6 This underscores why:
- The IIF method is essential over immunodot 1
- Confirmatory testing with IFA and/or endoscopic biopsy is necessary 1
- APCA positivity alone should not establish the diagnosis 6
Combined Testing Approach
The optimal diagnostic strategy combines APCA-IIF with IFA testing, achieving 86.4% sensitivity and 90.3% specificity together, with a negative predictive value of 95.6%. 3 This combined approach significantly outperforms either test alone.
Clinical Implications
Establishing the diagnosis of pernicious anemia is critical because: